OptiNose Inc (OPTN) Event July 08, 2022, 11:00 UTC (75% Positive) OPTINOSE, INC. (OPTN) Provides Update on deep for chronic Full text
Register to leave comments News bot Oct. 2, 2025, 12:01 p.m. 📋 OPTINOSE, INC. (OPTN) - Clinical Trial Update Filing Date: 2022-07-08 Accepted: 2022-07-08 07:00:48 Event Type: Clinical Trial Update Event Details: OptiNose Inc (OPTN) Announces Clinical Trial Update OptiNose Inc (OPTN) provided an update on its clinical development programs. Clinical Development Highlights: Drug Program: deep, XHANCEDiseases/Conditions: chronic, objective measures of diseaseCollaboration: Initial Results 🔬 Clinical Development Pipeline (OPTINOSE, INC.): Product Type Development Stage Therapeutic Area Source OPN-375 DRUG Phase PHASE3 Bilateral Nasal Polyposis ClinicalTrials.gov 💼 Business Developments: Partnership: Not availableAcquisition: Not availableLicensing: Not availableRegulatory ApprovalExecutive Changes: Not available Structured Data: Company Name: OptiNose IncCIK: 0001494650Ticker Symbol: OPTNPeriod End Date: 2022-07-08Document Type: 8-K
📋 OPTINOSE, INC. (OPTN) - Clinical Trial Update
Filing Date: 2022-07-08
Accepted: 2022-07-08 07:00:48
Event Type: Clinical Trial Update
Event Details:
🔬 Clinical Development Pipeline (OPTINOSE, INC.):
💼 Business Developments:
Structured Data: